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Abstract
Background: Diffuse myocardial fibrosis (DMF) is important in cardiovascular disease, however until recently could
only be assessed by invasive biopsy. We hypothesised that DMF measured by T1 mapping is elevated in isolated
systemic hypertension.
Methods: In a study of well-controlled hypertensive patients from a specialist tertiary centre, 46 hypertensive
patients (median age 56, range 21 to 78, 52 % male) and 50 healthy volunteers (median age 45, range 28 to 69,
52 % male) underwent clinical CMR at 1.5 T with T1 mapping (ShMOLLI) using the equilibrium contrast technique
for extracellular volume (ECV) quantification. Patients underwent 24-hours Automated Blood Pressure Monitoring
(ABPM), echocardiographic assessment of diastolic function, aortic stiffness assessment and measurement of
NT-pro-BNP and collagen biomarkers.
Results: Late gadolinium enhancement (LGE) revealed significant unexpected underlying pathology in 6 out of 46
patients (13 %; myocardial infarction n = 3; hypertrophic cardiomyopathy (HCM) n = 3); these were subsequently
excluded. Limited, non-ischaemic LGE patterns were seen in 11 out of the remaining 40 (28 %) patients.
Hypertensives on therapy (mean 2.2 agents) had a mean ABPM of 152/88 mmHg, but only 35 % (14/40) had left
ventricular hypertrophy (LVH; LV mass male > 90 g/m2; female > 78 g/m2). Native myocardial T1 was similar in
hypertensives and controls (955 ± 30 ms versus 965 ± 38 ms, p = 0.16). The difference in ECV did not reach
significance (0.26 ± 0.02 versus 0.27 ± 0.03, p = 0.06). In the subset with LVH, the ECV was significantly higher
(0.28 ± 0.03 versus 0.26 ± 0.02, p < 0.001).
Conclusion: In well-controlled hypertensive patients, conventional CMR discovered significant underlying diseases
(chronic infarction, HCM) not detected by echocardiography previously or even during this study. T1 mapping
revealed increased diffuse myocardial fibrosis, but the increases were small and only occurred with LVH.
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Background
Arterial hypertension is one of the most common car-
diovascular diseases and a major cause of morbidity and
mortality in the developed world. Arterial hypertension
results in increasing arterial stiffness and afterload,
leading to remodelling of the myocardium due to
cardiomyocyte hypertrophy, fibroblast stimulation and
then increased collagen formation. Progressive accumu-
lation of interstitial collagen fibres, i.e. diffuse myocar-
dial fibrosis (DMF), in left ventricular hypertrophy
(LVH) has been shown at necropsy [1] and endomyocar-
dial biopsy [2–4]. The cardiovascular magnetic reson-
ance (CMR) derived late gadolinium enhancement
(LGE) technique has shown patchy, non-specific or non-
ischaemic patterns of fibrosis in hypertension [5]. How-
ever, LGE is only able to detect relative increases be-
tween “normal” myocardium and focal scar and cannot
therefore be used to identify and quantify absolute
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diffuse fibrosis [6–8]. This problem can be now ad-
dressed by quantification of T1 relaxation time mapping
before and after gadolinium contrast administration and
subsequent quantification of extracellular volume (ECV).
Both ECV and native myocardial T1 have been shown to
closely reflect the degree of histologic DMF [9–12]. Pre-
liminary work on DMF in hypertension have described
elevated extracellular volume fraction (ECV) compared
to controls [13, 14]. However, this technique has not
been used to comprehensively assess a cohort of hyper-
tensive patients. We hypothesize that diffuse myocardial
fibrosis measured by T1 mapping and ECV quantification
is elevated in isolated systemic hypertension, correlates
with cardiac remodelling and established biomarkers, and
may therefore be a key biomarker in assessing the cardiac
effects of systemic hypertension.
Methods
All research was carried out at University College London
Hospital NHS Trust in collaboration with William Harvey
Research Institute at Queen Mary University of London
between April 2011 and February 2012. The study was ap-
proved by the ethical committee of UK National Research
Ethics Service and conformed to the principles of the
Helsinki Declaration (UK NRES 07/H0715/101). All sub-
jects gave written consent to participate in the study.
Hypertensive subjects were recruited prospectively
from a specialist hypertension clinic in a tertiary referral
hospital. All patients had been investigated for secondary
hypertension as part of their clinical work-up in the spe-
cialist hypertension clinic. Eligible patients were men
and women between 18 and 80 years of age with essen-
tial hypertension. In accordance with the 2011 UK
hypertension guidelines [15], ambulatory blood pressure
measurement (ABPM) was used to confirm diagnosis of
recruited patients (clinic blood pressure of ≥140/
90 mmHg and daytime ABPM of ≥135/85 mmHg) and
patients with “white coat” hypertension (not on anti-
hypertensive medications with a normal ABPM) were
excluded. Comprehensive assessment on the day of the
CMR consisted of clinical history, arterial stiffness and
blood pressure measurement following a period of rest,
transthoracic echocardiography, electrocardiogram (ECG),
blood tests (NT-pro-BNP, full blood count for the
haematocrit, renal function, and lipid profile), 6-
minute walk test (6MWT), and CMR (including equi-
librium diffuse myocardial fibrosis protocol). ECG was
analysed for LVH by Cornell product and Sokolow-Lyon
voltage criteria [16, 17].
A control group of healthy, normotensive volunteers
recruited from hospital, university, community and gen-
eral practice settings in Greater London, UK, were gen-
der matched to the hypertension cohort. None were
referred as patients for a clinical CMR scan that then
turned out to be normal. All normal subjects had no
history or symptoms of cardiovascular disease or dia-
betes. All subjects had a normal blood pressure (defined
as ≤140/90 mmHg), 12-lead ECG and clinical CMR scan.
Exclusion criteria for both groups included diabetes
mellitus, known ischaemic heart disease, contraindica-
tion to CMR (pacemakers) or gadolinium administration
(glomerular filtration rate <30 mL/min/m2). Healthy vol-
unteers were excluded if they had a history of cardiovas-
cular symptoms, an abnormal ECG or abnormal CMR.
CMR protocol
Standard CMR examinations were performed in all pa-
tients using a 1.5-T scanner (Avanto; Siemens Medical
Imaging, Erlangen, Germany) in line with standard CMR
protocols [18]. T1 mapping for CMR ECV quantification
was performed using the Shortened Modified Look-
Locker Inversion recovery technique (ShMOLLI) (21)
prior to contrast and at contrast equilibrium [9]. The
studies were performed by cardiologists with ≥2 years of
experience in CMR imaging (DS, SB, SW). Standard
LGE assessment using a fast low angle single shot inver-
sion recovery sequence was used to assess focal myocar-
dial fibrosis. Fifteen minutes after an initial contrast bolus
of 0.1 mmol/kg of gadoterate meglumine (Dotarem; Guer-
bet, Paris, France) during which LGE images were ac-
quired, an infusion of contrast at a rate of 0.0011 mmol/kg
per minute was administered during which time the pa-
tient was removed from the scanner. After a minimum of
30 minutes the patient was returned into the scanner and
equilibrium contrast T1 maps were acquired. The ECV
was calculated by: ECV = (1–haematocrit) x (1/ΔT1tissue)/
(1/ΔT1blood). Haematocrit was measured on the same day.
CMR image analysis
Left ventricular (LV) volumes, ejection fraction and mass
were calculated using standard techniques [18] and ana-
lysed using a thresholding method indexed to body surface
area. The presence of LGE was determined using the visual
assessment of two authors (TT and JCM, the latter of
whom has >10 years of CMR experience). For T1 measure-
ments, a region of interest (ROI) was manually drawn on
the septum on each image (TT) as shown in Fig. 1. Our
group has previously validated this method (23). Myo-
cardial feature tracking was performed by a blinded
experienced observer using dedicated vector-based ana-
lysis tool (2D performance analysis MR, Tomtec,
Unterschleissheim, Germany), as previously described
[19]. Briefly, based on a contour manually drawn by an
expert reader along the LV endocardial border of one
frame, the software automatically propagates the con-
tour and follows its features throughout the remainder
of the cardiac cycle. LV short axis circumferential and
radial strains were calculated from a mid-ventricular
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short-axis view containing both papillary muscles.
Strain values (% change from baseline) were obtained
for each segment and global values defined as the mean
of all segmental values.
Echocardiography
Echocardiography was performed on the day of the CMR
in all hypertensive subjects using a GE Vivid E9 system
(GE Healthcare, Wauwatosa, USA) with a 4-MHz trans-
ducer. Measurements were made according to European
Society of Echocardiography criteria [20]. Early (E) and
atrial (A) doppler mitral inflow wave velocities, pulmonary
vein doppler, and tissue doppler of septal and lateral mitral
annulus E’ and A’-wave velocities were recorded. Diastolic
function was graded according to the mitral inflow pat-
tern, pulmonary vein in-flow and tissue doppler indices at
the mitral valve annulus as previously described [21].
Arterial stiffness
Arterial stiffness was measured in hypertensive subjects
using the Vicorder device (Skidmore Medical Ltd, UK),
by registering carotid femoral pulse wave velocity
(PWV), central aortic blood pressure and augmentation
index as previously described and validated. (23, 24)
PWV is the most validated method to non-invasively
measure arterial stiffness. It is considered the gold stand-
ard assessment of aortic stiffness, as it is a relatively sim-
ple method with reported accuracy, reproducibility and
is also an independent and strong predictor of adverse
outcomes in a variety of common diseases, such as cor-
onary heart disease and hypertension [22, 23]. The mea-
surements were acquired in a separate quiet room after
a period of rest. Central blood pressure measurement
and aortic stiffness estimated by pulse wave velocity
(PWV) measurement are more predictive of cardiovas-
cular outcome than peripheral BP [23, 24].
Biomarkers
Serum levels of the N-terminal pro-hormone of pro-
brain-natriuretic-peptide (NT-pro-BNP) were measured
using a 2-site electrochemiluminescence immunoassay
on a Roche E170 analyzer. Collagen Type I (procollagen
type I carboxy-terminal propeptide, (PICP)) and Type III
(Amino terminal peptide of type III procollagen
((PIIINP)) synthesis were measured using commercially
available assays. The samples were collected at the time
of CMR visit, immediately centrifuged and plasma sam-
ples were stored at −80 °C.
Data analysis and statistics
Statistical analysis was performed in R programming
language for statistical computing (version 3.0.1, The R
Foundation for Statistical Computing) and SPSS version
21 (SPSS Inc, Chicago, Ill). Normality of continuous data
was assessed by visual inspection of the histograms and
confirmed by the Shapiro-Wilk test. Continuous vari-
ables were expressed as mean ± SD and non-parametric
variables as median with inter-quartile range. Group
mean comparisons were performed using Student’s t-test
(two groups) for normally distributed data or the Mann-
Whittney U test for skewed data. A probability value of
p < 0.05 was considered statistically significant. Simple
and multivariable linear regression models determined
relationships between LV mass index, native myocardial
T1 time, equilibrium myocardial T1 time and ECV as
outcome variables, using demographic data, laboratory
results and CMR measurements as exposure variables.
Results
Fifty-six well-controlled hypertensive patients were re-
cruited. Ten patients were subsequently excluded as they
were found to have white coat hypertension. Forty-six
patients and 50 healthy volunteers underwent the full
CMR protocol. Morphological, functional and LGE
Fig. 1 Native and post contrast T1 mapping and LGE imaging in hypertension. Basal short axis T1 maps acquired pre-contrast (a) and post
contrast (b) with ShMOLLI. Image c shows the corresponding FLASH LGE image. The dashed black line represents an example region of interest.
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assessment revealed unexpected significant underlying
pathology in 6 out of the 46 patients (13 %; chronic in-
farct (n = 3); hypertrophic cardiomyopathy (HCM, n = 3);
Fig. 2). These six patients were excluded from subse-
quent analysis. The remaining cohort comprised of 40
patients (median age 56, range 21 to 78, 52 % male) and
50 healthy volunteers (median age 45, range 28 to 69,
52 % male). Patient ethnicity was self-reported as Cauca-
sian/white in 72.5 %, Asian in 12.5 % and Afro-
Caribbean/black in 15 %. Fifteen (37.5 %) of the study
subjects were treated with angiotensin converting en-
zyme inhibitors, 11 (27.5 %) with angiotensin II antago-
nists, 25 (62.5 %) with calcium channel blockers, 11
(27.5 %) with thiazide diuretic, 10 (25 %) with beta-
blockers, 10 (25 %) with alpha-blockers 4 (10 %) with
loop diuretic, 2 (5 %) with moxonidine and 1 (2.5 %)
each with spironolactone, direct renin antagonist and
phenoxybenzamine. Seven patients were not on any
anti-hypertensive therapy. All clinical parameters are
summarized in Table 1.
Left ventricular remodelling
The conventional CMR parameters are shown in
Table 2. Hypertensive subjects had higher LV mass index
(83.9 ± 33.6 vs. 65.7 ± 14.5 g/m2, p < 0.01), maximal wall
thickness, LV mass to volume ratio (MVR), left atrial area
(LAA) measured in the horizontal long axis view, indexed
stroke volume (SV), but no significant differences in ejec-
tion fraction (EF) or indexed end-diastolic (EDV) and
end-systolic (ESV) volumes.
LVH (defined as LV mass index >90 g/m2 in males
and >78 g/m2 in females [25]) was found in 35 % of pa-
tients (14/40). Those who fulfilled LVH criteria had
higher maximal wall thickness, but also larger ventri-
cles (as expressed by ESV and EDV) and larger indexed
LAA (Table 3). Furthermore, this subgroup had higher
central blood pressure, higher QRS complex voltage on
ECG (by Sokolov and Cornell) and more advanced dia-
stolic dysfunction (p < 0.01) (Table 3).
Higher LV mass was associated with larger LV volumes
and LA size (Table 4): 10.3 g for each 10 ml increase
in ESV (p < 0.01), 7.4 g for each 10 ml increase in
EDV (p < 0.0001) and 5.4 g for each 1 cm2 increase in
LAA (p < 0.0001). The severity of diastolic dysfunction
(trans-mitral E/A ratio, tissue Doppler lateral E/E’ ratio)
and higher ECG voltage parameters (by Cornell and
Sokolov) also increased with higher LV mass (data not
presented). There were no differences between the groups
Fig. 2 Diagnosis of occult disease by LGE in patients with arterial hypertension. Standard late gadolinium enhancement assessment using a fast
low angle single shot inversion recovery sequence revealed six patients (13 % of cohort) with either hypertrophic cardiomyopathy (a-c) or infarct
pattern (d-f).
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in the systolic strain parameters derived from feature
tracking analysis, in particular in global longitudinal,
circumferential or radial strain.
Late gadolinium enhancement
On LGE imaging, and after exclusion of the six patients
with infarct and HCM LGE patterns (Fig. 2), 11 of the
remaining 40 hypertensive subjects (28 %) had non-
specific LGE either at the right ventricular insertion point,
papillary muscle or patchy mid-wall enhancement (Fig. 3).
These LGE patterns were seen more often with increasing
degrees of LVH, evidence of cardiac remodelling (higher
LV mass index, mass volume ratio, wall thickness) and in-
creased afterload (higher systolic and diastolic pressure,
and also augmentation index), but not with age, sex or
ethnicity. Healthy controls did not have LGE.
T1 mapping and ECV quantification
Native myocardial T1, equilibrium-contrast T1 and ECV
values are shown in Table 5. Native myocardial T1 was
similar in patients and controls (955 ± 30 ms versus 965 ±
38 ms; p = 0.16), however native myocardial T1 times were
longer in patients with LVH than in ones without LVH
(997 ± 27 ms vs. 948 ± 31 ms; p < 0.001). Equilibrium-
contrast myocardial T1 was shorter in patients than
controls (578 ± 37 ms vs. 618 ± 33 ms; p < 0.0001). The
difference was attributable to higher weight (86.6 ± 15.7 kg
vs. 75.9 ± 13.8 kg, p < 0.01), which resulted in higher abso-
lute total contrast dose, and to worse eGFR (81 ± 21 ml/
min/m2 vs. 91 ± 17 ml/min/m2, p < 0.05), which also
shortened equilibrium-contrast blood T1 (478 ± 56 ms vs.
517 ± 48 ms; p < 0.001).
The difference in ECV between the hypertensives
and controls did not reach significance (27.1 ± 2.7 % vs.
Table 1 Baseline clinical characteristics for healthy volunteers and hypertensives
Healthy volunteers Hypertensive
(n = 50) (n = 40) p value
Men 26 (52 %) 21 (53 %) 0.96
Age in years (IQR) 44 (32.0 to 54.8) 58.5 (49.0 to 65.5) <0.001
Ethnicity
Whites 41 (82 %) 28 (70 %) 0.12
Blacks 8 (16 %) 6 (15 %) 0.59
Asians 1 (2 %) 6 (15 %) 0.06
Height (cm) 171.9 ± 11.3 170.2 ± 9.1 0.41
Weight (kg) 75.9 ± 13.8 86.6 ± 15.7 <0.01
Body surface area (m2) 1.9 ± 0.2 2.0 ± 0.2 <0.05
Body mass index (kg/m2) 25.6 ± 3.2 29.8 ± 4.5 <0.0001
Systolic blood pressure (mmHg) 122.7 ± 10.5 152.0 ± 17.2 <0.0001
Diastolic blood pressure (mmHg) 74.1 ± 9.1 88.1 ± 10.7 <0.0001
eGFR (ml/min/1.73 m2) 91.2 ± 16.5 81.1 ± 20.8 <0.05
Haematocrit (%) 0.42 ± 0.03 0.42 ± 0.04 0.37
Number of antihypertensives (0/1/2/3/4/5/6) 7/5/13/7/4/3/1
Table 2 Cardiovascular Magnetic Resonance Parameters
Healthy volunteers Hypertensive
(n = 50) (n = 40) p value
EDV index (ml/m2) 73.2 ± 13.6 71.2 ± 17.0 0.7
ESV index (ml/m2) 25.0 (IQR: 21.0 to 29.75) 21.8 (IQR: 15.3 to 28.1) 0.13
LVEF (%) 66.5 ± 5.8 69.0 ± 8.9 0.12
LAA index (cm/m2) 11.1 ± 1.8 11.7 ± 2.5 0.16
Maximal wall thickness (mm) 6.7 ± 1.2 11.9 ± 2.4 <0.001
LV mass index (g/m2) 65.0 (IQR: 55.3 to 74.5) 76.9 (IQR: 66.5 to 88.4) <0.001
LV mass/EDV (g/ml) 0.91 (IQR: 0.77 to 1.04) 1.09 (IQR: 0.93 to 1.31) <0.001
LV hypertrophy 0 14 (35 %)
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Table 3 Hypertensives without versus Hypertensives with LVH
Hypertensives no LVH Hypertensives with LVH
n = 26 n = 14 p-value
T1 mapping
T1 Blood (ms) 1564 ± 61 1614 ± 83 0.02
T1 Myocardium (ms) 948 ± 31 997 ± 27 <0.001
ECV by ShMOLLI (%) 26.2 ± 2.2 28.8 ± 2.8 <0.01
Clinical
Men 16 (62 %) 5 (35 %) 0.12
Age in years (IQR) 57.8 ± 12.2 53.2 ± 17.5 0.4
Height (cm) 171 ± 10.4 168.5 ± 6.1 0.44
Weight (kg) 86.6 ± 16.9 86.6 ± 13.8 1
Body surface area (m2) 2.02 ± 0.24 2.01 ± 0.18 0.79
Body mass index (kg/m2) 29.5 ± 4.7 30.4 ± 4.2 0.49
Systolic blood pressure (mmHg) 150.1 ± 18.0 155.5 ± 15.7 0.35
Diastolic blood pressure (mmHg) 87.1 ± 11.7 90.0 ± 8.4 0.35
eGFR (ml/min/1.73 m2) 83.6 ± 18.8 76.4 ± 24.2 0.23
Haematocrit (%) 0.43 ± 0.03 0.42 ± 0.05 0.39
Number of antihypertensives (0/1/2/3/4/5/6) 3/5/8/6/2/1/1 4/0/5/1/2/2/0
CMR
EDV index (ml/m2) 66.2 ± 11.7 82.5 ± 20.5 0.02
ESV index (ml/m2) 19.9 ± 7.2 29.4 ± 14.4 0.05
LVEF (%) 70.7 ± 7.3 65.9 ± 10.9 0.16
LAA index (cm/m2) 10.9 ± 2.1 13.3 ± 2.5 <0.01
Maximal wall thickness (mm) 10.9 ± 1.6 13.8 ± 2.6 <0.001
LV mass index (g/m2) 68.6 ± 11.8 112.4 ± 39.6 <0.001
LV mss/EDV (g/ml) 1.07 ± 0.26 1.41 ± 0.5 0.05
Transverse strain 34.0 ± 11.8 30.8 ± 9.4 0.21
Longitudinal strain −18.7 ± 5.4 −17.4 ± 3.8 0.41
Circumferential strain −24.7 ± 5.3 −24.6 ± 3.8 0.64
Radial strain 37.3 ± 13.1 35.4 ± 7.1 0.94
Late enhancement, n (%) 5 (19) 6 (43) 0.15
Electrocardiogram
Sokolov-Lyon index 22.3 ± 4.8 32.5 ± 13.1 <0.01
Cornell voltage criteria 13.7 ± 5.2 21.1 ± 8.7 <0.01
Aortic stiffness
Pulse wave velocity 7.7 ± 1.5 8.4 ± 1.6 0.15
Augmentation index 17.0 ± 5.7 13.6 ± 6.6 0.18
Aortic systolic blood pressure (mmHg) 141.5 ± 14.9 167.4 ± 27.2 <0.01
Aortic pulse pressure (mmHg) 54.6 ± 13.4 64.3 ± 17.2 0.13
Diastolic function on echocardiogram
E/A 0.9 ± 0.3 1.1 ± 0.5 0.7
E/e’ septal 10.3 ± 2.9 12.9 ± 7.3 0.36
E/e’ lateral 8.0 ± 2.3 12.9 8 ± 6.4 <0.01
Diastolic grade (I/II/III/IV) 3/18/5/0 0/6/7/1 <0.01
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26.1 ± 2.4 %, p = 0.06). Hypertensive patients with LVH
had higher ECV than the ones without LVH (28.8 ± 2.8 %
vs. 26.2 ± 2.2 %, p < 0.01).
The relationship between T1 mapping and clinical pa-
rameters are summarized in Table 4:
Longer native myocardial T1 was associated with
the presence of LVH (β = 44.3, p < 0.0001) and LVH
measures: higher maximal wall thickness (β = 2.89, p <
0.01) and LV mass index (β = 0.4, p < 0.01). Native myo-
cardial T1 was also prolonged with higher E/e’ ratio in the
lateral wall (β = 3.2, p < 0.01), higher central aortic pressure
(β = 0.7, p < 0.01) and higher ECG voltage sum by Cornell
(β =1.13, p = 0.01). The associations with indexed left atrial
area (β = 3.12, p = 0.06), E/A ratio (β = −0.15, p = 0.99) and
E/e’ septum (β = 1.81, p = 0.14) were not significant.
Equilibrium-contrast myocardial T1 was shorter in
older subjects (β = −0.09 per year, p < 0.001), in Afro-
Caribbean/blacks (β = −37.5, p < 0.05) and subjects
with LVH (β =2.65, p < 0.001). Equilibrium-contrast
myocardial T1 shortened by 5 ms for each millimetre in-
crease in maximal wall thickness (p < 0.001), by 7.6 ms for
10 mmHg higher systolic blood pressure (p < 0.001) and
by 11.5 ms for each 10 mmHg higher diastolic blood pres-
sure (p < 0.01). It was also shorter with worsening eGFR
(β = 0.88, p < 0.0001) and strongly associated with equi-
librium-contrast blood T1 time (β = 0.66, p < 0.0001),
however after adjustment, only the equilibrium-contrast
blood and myocardium T1 times remained their associ-
ation (β = 0.6, p < 0.0001). There was neither an associ-
ation between equilibrium-contrast myocardial T1 and
left atrial area (β = −0.59, p = 0.77) nor parameters of dia-
stolic dysfunction.
ECV was higher in women (β = 1.27, p < 0.05) and
Afro-Caribbean/blacks (β = 4.1, p < 0.0001). Taller sub-
jects had lower ECV (β = −0.05 per cm, p < 0.05). One %
increase in haematocrit was associated with 0.23 % reduc-
tion in ECV (p < 0.01). Similarly to equilibrium-contrast
myocardial T1, ECV increased with LV hypertrophy:
Table 4 Univariate Predictors of T1 mapping Parameters and Left Ventricular Hypertrophy
Native myocardial T1 Equilibrium myocardial T1 ECV LV mass index
Univariable Univariable Univariable Univariable
beta p beta p beta p beta p
Men −9.2 0.2 2.49 0.77 −1.27 <0.05 18 <0.001
Age per year −0.22 0.32 −0.09 <0.001 0 0.18 −0.15 0.39
Ethnicity 9.45 0.11
Asian −3.5 0.76 0.46 0.5 0.97 0.89
Black/Afrocaribbean −37.5 <0.05 4.07 <0.0001 37.45 <0.001
Height (cm) −0.13 0.72 0.61 0.14 −0.05 <0.05 0.46 0.08
Weight (kg) 0.11 0.64 −0.82 <0.01 −0.03 0.14 0.51 <0.01
Body surface area (m2) 4.13 0.8 −39.5 <0.05 −2.0 0.09 35.0 <0.01
Body mass index (kg/m2) 0.74 0.37 −4.75 <0.0001 −0.02 0.72 1.48 <0.05
Systolic blood pressure (mmHg) 0.13 0.5 −0.76 <0.001 0.01 0.33 0.37 <0.05
Diastolic blood pressure (mmHg) 0.07 0.81 −1.15 <0.01 0.01 0.62 0.60 <0.05
eGFR (ml/min/1.73 m2) 0.09 0.66 0.88 <0.0001 −0.03 0.09 −0.42 <0.01
Hematocrit (%) −0.94 0.42 0.38 0.8 −0.23 <0.01 179.7 <0.05
EDV index (ml/m2) 0.35 0.15 0.08 0.77 0.03 0.9 0.74 <0.0001
ESV index (ml/m2) 0.23 0.55 0.13 0.77 0.01 0.67 1.03 <0.001
LVEF (%) 0.09 0.85 −0.18 0.76 0.04 0.32 −0.68 0.06
LAA index (cm/m2) 3.12 0.06 −0.59 0.77 0.34 <0.01 5.14 <0.0001
Maximal wall thickness (mm) 2.89 <0.01 −5.02 <0.0001 0.18 <0.05 – –
LV mass index (g/m2) 0.40 <0.01 −0.33 <0.05 0.02 <0.05 – –
LVH (presence) 44.26 <0.0001 −28.8 <0.05 2.65 <0.001 – –
E/A ratio −0.15 0.99 16.2 0.3 -0.001 0.9 40.2 <0.01
E/e’ septum 1.81 0.14 −1.51 0.2 0.002 0.08 3.18 <0.01
E/e’ lateral wall 3.21 <0.01 −1.23 0.3 0.001 0.3 3.76 <0.001
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maximal wall thickness (β = 0.18 per mm, p < 0.05), LV
mass index (β = 0.02, p < 0.05) and with Cornell’s index
(β = 0.12, p < 0.05). ECV also increased by 0.34 % for
each 1 cm/m2 increase in LAA (but there was no signifi-
cant association with parameters of diastolic dysfunction).
ECV was independent of eGFR and blood pressure values.
After adjustment only Afro-Caribbean race (β = 2.94,
p < 0.01), height (β = −0.06, p < 0.05) and native T1 time
(β = 0.04, p < 0.0001) were associated with ECV.
Functional status and biomarkers
ECV also predicted functional status was predicted by
ECV, with a one per cent in ECV shortening the distance
Fig. 3 Non-ischaemic, non-HCM pattern of late gadolinium enhancement. Standard late gadolinium enhancement assessment using a fast low
angle single shot inversion recovery sequence revealed non-ischaemic, non-HCM pattern of focal fibrosis in 13 % of the hypertensive cohort, with
LGE in the papillary muscles (A + B) mid-wall (B + C) and right ventricular insertion points (d).
Table 5 T1 Mapping Parameters
Healthy Volunteers Hypertensive
(n = 50) (n = 40) p value
Pre-contrast/Native
T1 Blood (ms) 1568 ± 71 1581 ± 72 0.4
T1 Myocardium (ms) 955 ± 30 965 ± 38 0.16
Post-contrast at
Equilibrium
T1 Blood (ms) 517 ± 48 478 ± 56 <0.001
T1 Myocardium (ms) 618 ± 33 578 ± 37 <0.001
ECV by ShMOLLI (%) 26.1 ± 2.4 27.1 ± 2.7 0.06
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on the 6-MWT by 14 meters (p < 0.05). Native and equi-
librium T1 times were not associated with worsening
functional status.
NT-pro-BNP was only available for the hypertensive
cohort and ranged between 4 and 100 (median 8 pmol/
L). NT-pro-BNP was higher in hypertensives with
LVH than without LVH (26.9 ± 16.4 vs 12.0 ± 19.6
pmol/L, p < 0.001). Log-transformed NT-pro-BNP cor-
related very weakly with markers of DMF (native myo-
cardial T1, β = 0.005, p < 0.01; equilibrium-contrast T1
β = −0.004, p < 0.05; ECV β = 0.05, p < 0.05).
Collagen biomarkers were available for ten healthy
volunteers and 31 patients. PICP (43.0 ± 3.9 vs 54.3 ±
2.3ug/L, p = 0.02) and PIIINP (3.7 ± 0.1 vs 4.5 ± 0.2ug/L,
p < 0.01) were higher in patients than in the healthy con-
trols. There was no significant difference between LVH+
ve and LVH-ve hypertensive patients. There was no asso-
ciation between collagen biomarker levels and myocardial
T1 mapping parameters.
Discussion
This study has shown that DMF assessed by T1 map-
ping increases in hypertensive patients, but that the
changes were small, and occurred only in those with
LVH, in keeping with prior findings using other modal-
ities [26].
This study was of well-controlled isolated hyperten-
sion. Conventional CMR with LGE frequently adds
value by identifying other pathologies – here that value
was unexpectedly high – 13 % of patients had new
diagnoses of hypertrophic cardiomyopathy or silent in-
farction. Although echocardiography is the first im-
aging modality for the assessment of LVH due to
greater availability and smaller cost, CMR is the gold
standard for LV volume and function assessment and
has the advantage of allowing tissue characterisation
with LGE and T1 mapping.
After exclusion of these other pathologies, 11 of the
remaining 40 hypertensive subjects (28 %) had non-
specific patchy LGE either at the right ventricular in-
sertion point, in the papillary muscles or LV mid-wall
enhancement. Although there is no data on the pre-
dictive value of non-ischaemic LGE in isolated arterial
hypertension, it tracked increasing degree of LV
hypertrophy and LV afterload. Furthermore, non-
ischaemic LGE in the prototypical LV afterload disease
of aortic stenosis is predictive of mortality [27].
Hypertensive patients had lower equilibrium-contrast
myocardial T1 and a trend to higher ECV. Native myo-
cardial T1 and ECV values (but not post-contrast T1)
were higher in hypertensives with than without LVH.
Native T1 is a composite signal of the intra- and extra-
cellular myocardial compartments, whereas after admin-
istration of contrast (equilibrium-contrast T1 and ECV)
the signal from the extra-cellular space dominates. The
lower equilibrium-contrast T1 values in hypertensives
were attributable to increased weight (increased contrast
bolus) and worse renal function. The results suggest that
hypertensive patients have increased myocardial fibrosis
(both focal and diffuse), but that really this is triggered
with the onset of LVH rather than earlier in the pathogen-
esis. There was some signal from those without LVH –
but rather than being an early sign, this could be residual
from fibrosis prior to LVH regression. In contrast to re-
cent findings by Kuruvilla et al. [28], who found reduced
peak systolic circumferential strain in LVH+ ve hyperten-
sive patients compared to LVH-ve and controls, we did
not find a significant difference, which may be due ag-
gressive anti-hypertensive treatment with associated
anti-fibrotic effects (70 % of LVH + ve patients were on
an ACE-inhibitor/angiotensin II or aldosterone receptor
antagonist).
Ultimately, the size of the study, severity of the dis-
ease and level of control of hypertension (65 % of our
subjects had no LVH) rendered this study under-
powered to further elucidate all the questions; specifically,
there was a lack of significant and consistent association
across parameters of T1 mapping and diastolic dysfunc-
tion as well as strain. Diffuse fibrosis appears not to be a
major early player in treated hypertensive heart disease
prior to the onset of LVH. A larger prospective study
would be necessary to scrutinise changes prior to and post
therapy.
The T1 mapping field is rapidly advancing. The signal
is very large in amyloid, increased in iron load,
Anderson-Fabry disease, myocarditis and focal fibrosis
(e.g. infarction), but smaller in diffuse fibrosis. This
study suggests current technology is hitting limits for
subtle changes, such as might be seen in well-controlled
hypertension without LVH. Several positive studies have
been published [29–31], but highlighting technological
limits is as important and this effectively negative study
has taken longer to get submitted than mainly positive
studies, a common bias in new research fields.
Study limitations and perspective
Patients were recruited from a specialist hypertension clinic
and therefore had very well-controlled disease with docu-
mented good adherence to medication. A significant num-
ber of patients were on anti-hypertensive medications,
which are attributed to have anti-fibrotic effects, which may
have resulted in a reduction of LVH and ECV compared to
untreated subjects, however the sample size was too small
to explore this. We used good technology – ShMOLLI T1
mapping with equilibrium imaging. But the use of the equi-
librium infusion technique, which requires re-positioning
of the patient and does not allow co-registration of pre and
post contrast maps, is not necessary for this disease. We
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now know the equilibrium is un-necessary for low ECV in-
creases [32, 33]: recent work by our group and others has
shown that the bolus-only technique has good agreement
with histological fibrosis, with a small degree of ECV over-
estimation in the high ECV range [32–34]. Whether the lat-
est techniques with new adiabatic pulses, sampling
schemes, motion correction, new reconstructions (e.g. T1*
for blood), ECV mapping and new methodologies to min-
imise partial voluming errors will make a difference is un-
known currently [35].
Conclusion
In well-controlled hypertensive patients, conventional
CMR discovered significant underlying diseases (chronic
infarction and HCM). T1 mapping based assessment
suggested small increases in DMF, occurring only in those
patients with LVH. This study highlights that interstitial
changes in early hypertension (pre-LVH) are small and
not detectable by current iterations of T1 mapping
technique.
ENDNOTE - Biomarker description
Carboxy-terminal propeptide of procollagen type I
(PICP): Levels were measured in EDTA plasma by sand-
wich enzyme linked immunosorbent assay (ELISA) KIT
manufactured by USCN Life Science Inc, Democratic
Republic of China). The minimal detectable level of
26.6 pg/mL.
Amino-terminal peptide of type III procollagen (PIIINP):
Levels were measured in EDTA plasma using a competi-
tive radioimmunoassay (RIA) assay manufactured by
Orion Diagnostica, Finland. The minimal detectable level
was 0.3ug/L.
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